Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
COVID-19; COVID-19; This is a spontaneous report received from a consumer, Program ID. A 60-year-old female patient received BNT162b2 Omicron (KP.2) (COMIRNATY (2024-2025 FORMULA)), on 03Oct2024 as dose 1, single (Batch/Lot number: unknown) at the age of 59 years for COVID-19 immunisation. The patient's relevant medical history included: "COVID-19", start date: 2022 (unspecified if ongoing). There were no concomitant medications. Past drug history included: Paxlovid, start date: Jul2022, for COVID-19 treatment. Vaccination history included: COVID-19 vaccine (Primary immunization series complete; unknown manufacturer), for COVID-19 immunization; Moderna (DOSE NUMBER UNKNOWN (BOOSTER)), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Feb2025, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: Weight: About 155. The patient had nirmatrelvir/ritonavir (PAXLOVID) before and then she started with a couple of years ago and that she got all her boosters. The patient guesses that she can get COVID-19 again. So, she had PAXLOVID before and she has COVID-19 and PAXLOVID again. Therapeutic measures included nirmatrelvir/ritonavir (300/100 mg), oral, at 3 tablets, twice daily, for 5 days from 06Feb2025 (ongoing).
Medical History/Concurrent Conditions: COVID-19
Test Name: Weight; Result Unstructured Data: Test Result:About 155